Pharma’s dirtiest secret is in its pipes — and the fix is a flexible, multi‑stage wastewater factory

Regulatory limits and reuse economics

Pharmaceutical manufacturing uses vast amounts of water and generates highly variable, heavily contaminated wastewater. Water scarcity and rising treatment costs are forcing drugmakers to tighten effluent controls — and to chase reuse. One industry report notes that pharmaceutical R&D can discharge several tons of effluent per day, pushing firms toward “zero liquid discharge” approaches that reclaim water for reuse (Pharma Manufacturing). Recyclers can slash disposal costs by about 15× and reclaim over 90–98% of process water (Pharma Manufacturing) (Pharma Manufacturing).

Regulators are tightening screws, too. In Indonesia, PP No.22/2021 requires all polluting industries to build wastewater treatment plants (Atlantis Press). The environment ministry’s effluent standards (Permen LH No. 5/2014) set strict limits for pharmaceutical makers: for active‑ingredient production, BOD₅ ≤100 mg/L, COD ≤300 mg/L, TSS ≤100 mg/L, total N ≤30 mg/L, phenol ≤1.0 mg/L, and pH 6–9 (Scribd). Separate limits apply to formulation units — for example, BOD 75 mg/L, COD 150 mg/L, and TSS 75 mg/L (Scribd).

Raw wastewater variability and risk

Pharma effluent isn’t just dirty; it’s erratic. Streams can carry acids, bases, solvents, surfactants, nutrients, and trace active pharmaceutical ingredients (APIs) from reactor flushes, fermenters, extractions, equipment cleaning, lab waste, and more (Pharma Manufacturing). Reported raw concentrations are extreme: one survey in India found BOD₅ typically in the hundreds to >1300–1800 mg/L, and COD in the multi‑thousands to tens of thousands mg/L (ResearchGate). In one sample, COD was 40,000–60,000 mg/L (ResearchGate). Suspended solids can reach 800–1100 mg/L (ResearchGate), and pH has been measured from as low as 3.1 up to ~7.5 (ResearchGate). Both organic and inorganic loads can swing by factors of 2–5 depending on batch schedules or cleaning cycles.

Equalization and pH neutralization design

The backbone of a flexible plant is a large equalization (EQ) basin — a hold tank sized to dampen diurnal flow and concentration spikes so downstream processes see a steady load. Design typically targets 4–12 hours of average‑flow storage (EPA NEPIS) (EPA NEPIS) (EPA NEPIS). Mixing/aeration prevents settling and homogenizes pH. Integrated neutralization doses acid or alkali to 6.5–8.0 using automated controls — critical because raw pH 3–4 is not uncommon (ResearchGate). Neutralization safeguards sensitive biology and ensures the final pH 6–9 band required by regulators (Scribd), typically via precise addition with a dosing pump.

Primary solids and oil management

Upfront physical separation matters. Coarse screening and grit removal protect downstream equipment; facilities often pair headworks with primary separation hardware. Screens can be manual or continuous — a manual screen for low flows, or an automatic screen for continuous debris removal. Where fats/oils or high TSS appear during cleaning batches, a grease trap helps: a grease trap can remove 90%+ grease from kitchen‑type streams and prevent sewer blockages.

Many plants then add a Dissolved Air Flotation (DAF) unit — a tank that floats fine solids and oils after chemical coagulation — or opt for sedimentation. In practice, DAF with a coagulant can remove a large share of suspended solids, oils, and associated BOD in one step, on the order of 50–80% depending on the site (Clearfox). A compact DAF system fits this role; where settling is preferred, a clarifier provides primary sedimentation. Coagulant choice shapes performance, and many operators standardize with a plantwide coagulant program. Note that DAF mainly targets suspended and colloidal matter; persistent dissolved organics and metals are handled later (Clearfox).

Anaerobic first stage performance

The core treatment is multi‑stage biology. Given the high COD (chemical oxygen demand) typical in pharma effluent, an anaerobic first stage is often warranted. Anaerobic reactors — such as UASB (upflow anaerobic sludge blanket) or packed‑bed/expanded granular systems — convert organics to biogas and can remove roughly 50–70% of COD at high strength (ResearchGate). A published upflow anaerobic packed‑bed treating pharmaceutical wastewater achieved about 60–73% COD removal at moderate organic loading rates (PMC). This step also lowers BOD and hardness, cutting later aeration costs. Care is needed to acclimate biomass, since some APIs or sanitizers inhibit anaerobes; modular anaerobic digestion systems allow staged adaptation.

High‑rate aerobic treatment and nutrient control

Downstream, a high‑rate aerobic reactor completes oxidation and enables nitrogen removal. A conventional activated sludge design with sludge age ~10–20 days and hydraulic residence ~6–8 hours can achieve >90% removal of remaining BOD/COD, while nitrifying ammonia and — if an anoxic zone is included — denitrifying nitrate to reduce total nitrogen. Phenol and other constituents can biodegrade here, though higher toxicity may require extra retention. Typical effluent from a well‑run aerobic stage has BOD₅ <20–30 mg/L with COD well below regulatory caps. Common platforms include activated sludge basins and moving bed bioreactors (MBBR), with an optional nutrient removal configuration if total N limits apply.

PAC addition for recalcitrant compounds

Even after biology, traces of recalcitrant organics and APIs can persist. A powdered activated carbon (PAC) step adsorbs these. In practice, PAC is dosed into the aeration tank mixed liquor or a separate contact basin. Full‑scale data show that continuous addition of a few mg PAC per mg DOC (roughly 1–2 mg PAC per liter influent) reduced refractory drug residues by ~60–80% in an activated sludge reactor (ResearchGate). Specifically, carbamazepine fell 63–83% and diclofenac ~67–69% at PAC doses of 0.7–2.6 mg per mg DOC (ResearchGate). The trial reported negligible negative impact on nitrification or aeration energy; sludge production rose only ~7–9%. Plants typically purge spent PAC with waste sludge and replenish; a bulk activated carbon program standardizes sourcing and handling.

Membrane and oxidation polishing

For final polishing, membranes and advanced oxidation add barriers. A membrane bioreactor (MBR) combines biological treatment with ultrafiltration to physically remove nearly all residual suspended solids and pathogens; many operators integrate MBR units or post‑stage ultrafiltration. To target dissolved micropollutants at low parts‑per‑billion, nanofiltration (NF) and reverse osmosis (RO) are used; studies report RO removes >95–99% of many drugs (ibuprofen >99%, diclofenac ~95%) (PMC). Here, an engineered train might deploy nano‑filtration followed by RO within integrated membrane systems.

Advanced oxidation processes (AOP) — ozonation (often with hydrogen peroxide) or UV/H₂O₂ — break down persistent organics. Bench studies show that an O₃/H₂O₂ “peroxone” step can achieve ~75–90% additional COD reduction in minutes, especially when followed by activated carbon polishing (PMC). In one hybrid treatment, ozone+peroxide yielded 75–88% COD removal and activated carbon afterward raised total COD removal to ~85–93% (PMC). A common multi‑barrier configuration is MBR → (NF/RO or O₃/UV) → UV disinfection; packaged ultraviolet systems complete disinfection without chemicals.

Design metrics and compliance outcomes

What does success look like? If raw COD is 10,000 mg/L, the plant must drive it to <300 mg/L — a ~99% reduction to meet the strictest Indonesian limits for formulation units. A typical path: ~60% COD removal anaerobically (down to ~4,000 mg/L), ~75–90% of the remainder biologically (to <500 mg/L), then PAC/AOP to hit <300 mg/L. BOD₅ typically falls below 30 mg/L and TSS <50 mg/L. Effluent pH is buffered to ~6.5–8.5 by design. Nutrients (N, P) are reduced via nitrification/denitrification and, where needed, chemical precipitation (e.g., lime).

Each step’s performance is backed by data: mature activated sludge removes >90% BOD; PAC dosing removes >60% of remaining target compounds (ResearchGate); NF/RO rejects >95% of residual pharmaceuticals (PMC); and AOP can further cut COD by ~80–90% (PMC). One Indonesian study found that an engineered WWTP using this modular layout consistently met all MOE pharmaceutical effluent standards (Migration Letters).

Operational flexibility and controls

Variability demands flexibility. Plants automate flow, pumping, and pH control; parallel reactor trains enable maintenance without shutdown. Online sensors (TOC/COD, pH, ORP) can divert toxic spikes back to EQ or into an emergency holding tank. Sludge storage and handling accommodate solids from DAF, biomass, and spent PAC. In practice, a modular flow — screen → EQ/neutralization → DAF → anaerobic → aerobic + PAC → MBR/filtration → advanced oxidation/disinfection — provides redundancy and robustness against feed changes.

In quantitative terms, the multi‑stage plant reduces COD/BOD by over 95% and removes nearly all solids and drug residues. In combination, anaerobic + aerobic stages, PAC, and polishing cut persistent pharmaceuticals by >80% overall (ResearchGate) (PMC), a level that satisfies Indonesian and international water‑quality goals.

Sources and further reading

Sources: Maskun et al., Water 2025; Hook, Pharma Manufacturing 2022 (Pharma Manufacturing) (Pharma Manufacturing); Tito et al. (industry guidelines); Permen LH No.5/2014 (Scribd) (Scribd); Gupta et al., Phytobionts 2019 (ResearchGate) (ResearchGate); Rizky et al., ICOSEND2024 (Atlantis Press) (Atlantis Press); Paikun et al., Migration Letters 2024 (Migration Letters); Campinas et al., JWPE 2022 (ResearchGate); Belete et al., Environ. Systems Res. 2023 (PMC); Patel et al., ACS Omega 2020 (PMC).